IL-6 hypothesis looking shaky as Kevzara fails COVID-19 trialHopes that already-approved drugs targeting IL-6 could be repurposed to treat COVID-19 have been undermined by disappointing results Share XIL-6 hypothesis looking shaky as Kevzara fails COVID-19 trialhttps://pharmaphorum.com/news/il-6-hypothesis-looking-shaky-as-kevzara-fails-covid-19-trial/
AI health record scanning could identify pancreatic cancer earlyArtificial intelligence (AI) could hold the key to identifying people at risk of pancreatic cancer early, allowing them Share XAI health record scanning could identify pancreatic cancer earlyhttps://pharmaphorum.com/news/ai-health-record-scanning-could-identify-pancreatic-cancer-early/
Novartis pays $678 million to settle US kickback allegationsAnother nail has been hammered into the coffin of the pharma model of providing lavish entertainment and other Share XNovartis pays $678 million to settle US kickback allegationshttps://pharmaphorum.com/news/novartis-pays-678-million-to-settle-us-kickback-allegations/
Boots, Macmillan offer free video consultations to cancer patientsPeople living with cancer will be able to access free video consultations in their own homes under a Share XBoots, Macmillan offer free video consultations to cancer patientshttps://pharmaphorum.com/news/boots-macmillan-offer-free-video-consultations-to-cancer-patients/
Indivior ex-CEO could face jail time after opioid convictionThe resignation of Indivior chief executive Shaun Thaxter this week was swiftly followed by a guilty plea – Share XIndivior ex-CEO could face jail time after opioid convictionhttps://pharmaphorum.com/news/indivior-ex-ceo-could-face-jail-time-after-opioid-conviction/
Celebrations as NHS England agrees deal for Vertex’ cystic fibrosis tripleNHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after Share XCelebrations as NHS England agrees deal for Vertex’ cystic fibrosis triplehttps://pharmaphorum.com/news/celebrations-as-nhs-england-agrees-deal-for-vertex-cystic-fibrosis-triple/
US Congress faces pressure to maintain telehealth after COVID-19The coronavirus pandemic has forced healthcare systems around the world to make greater use of telehealth services during Share XUS Congress faces pressure to maintain telehealth after COVID-19https://pharmaphorum.com/news/us-congress-faces-pressure-to-maintain-telehealth-after-covid-19/
Gilead finally breaks its silence on remdesivir’s priceAfter weeks of speculation, Gilead Sciences has revealed its pricing plans for coronavirus drug remdesivir – and the Share XGilead finally breaks its silence on remdesivir’s pricehttps://pharmaphorum.com/news/gilead-finally-breaks-its-silence-on-remdesivirs-price/
As CHMP backs Vertex’ CF triple, campaigners plead for speedy UK dealCystic fibrosis patient groups in the UK are celebrating a recommendation by the EMA’s human medicines committee to Share XAs CHMP backs Vertex’ CF triple, campaigners plead for speedy UK dealhttps://pharmaphorum.com/news/as-chmp-backs-vertex-cf-triple-campaigners-plead-for-speedy-uk-deal/
